Edgewise Therapeutics at Guggenheim conference: trial design aims wider HCM reach

🌐 Investing.com (Cyprus) —
Edgewise Therapeutics at Guggenheim conference: trial design aims wider HCM reach

AI Summary

Edgewise Therapeutics discussed clinical-trial design at a Guggenheim conference, with a focus on potentially extending its hypertrophic cardiomyopathy program to a broader patient population. The headline provides no trial results or specific design details.

Markets Health Edgewise Therapeutics hypertrophic cardiomyopathy HCM clinical trial trial design Guggenheim conference

Read original source →